BLCA tumors with high YY1 expression on the other hand, exhibited a reverse profile in the pathway activity scores of the cell cycle pathway and DNA damage pathway (higher PAS), as well as lower PAS in the EMT and hormone ER pathways, compared to BLCA tumors with lower YY1 expression (Figure 2B). The gene discussed is YY1; the disease is bladder transitional cell carcinoma.